van Dijk H, Bakker I A, Testerink J, Bloksma N, Willers J M
J Immunol. 1975 Dec;115(6):1587-91.
Oxisuran was tested in a TAR system and for the DH on SRBC. Besides immunosuppressive properties in the TAR and DH also mentioned by other authors, stimulation was found after prolonged administration. No effect of oxisuran on the humoral response was observed. The action of oxisuran was suggested to be indirect, effected by stimulation of the PAG system. Adrenalectomy of mice made animals non-liable for oxisuran action measured in the TAR assay. Oxisuran caused an increase of the corticosterone plasma level with a peak after four daily injections. This was paralleled by a peak in adrenal gland weight and a minimum in thymus size. The reduction in these effects after five injections (tachyphylaxis) suggest that a feedback mechanism is involved. Comparison of thymus weights after oxisuran and corticosterone administration indicates that a daily dose of 100 mg oxisuran/kg corresponds with 1.5 mg corticosterone/kg. The effects of oxisuran in the TAR and on the DH and the feedback phenomenon could be imitated with 1.5 mg corticosterone/kg. The mononuclear phagocyte has been proposed as the main target cell of oxisuran action, mediated by the PAG system.
奥昔舒仑在TAR系统中进行了测试，并用于对SRBC的迟发型超敏反应（DH）测试。除了其他作者也提到的在TAR和DH中的免疫抑制特性外，长期给药后还发现了刺激作用。未观察到奥昔舒仑对体液反应的影响。奥昔舒仑的作用被认为是间接的，通过刺激PAG系统实现。对小鼠进行肾上腺切除术，使动物在TAR试验中对奥昔舒仑的作用不敏感。奥昔舒仑导致血浆皮质酮水平升高，在每日注射四次后达到峰值。这与肾上腺重量的峰值和胸腺大小的最小值同时出现。五次注射后这些效应的降低（快速耐受性）表明涉及一种反馈机制。比较奥昔舒仑和皮质酮给药后的胸腺重量表明，奥昔舒仑的每日剂量为100mg/kg相当于皮质酮1.5mg/kg。奥昔舒仑在TAR和DH中的作用以及反馈现象可以用1.5mg/kg的皮质酮来模拟。单核吞噬细胞已被认为是奥昔舒仑作用的主要靶细胞，由PAG系统介导。
